<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2468">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616001</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-IVIG VENT</org_study_id>
    <secondary_id>2010902</secondary_id>
    <nct_id>NCT04616001</nct_id>
  </id_info>
  <brief_title>IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation</brief_title>
  <official_title>Pilot Study of the Use of IVIG in Patients With Severe COVID-19 Infections Requiring Mechanical Ventilation and to Assess Their Biological Responses to IVIG Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Pilot Study is to establish a hypothesis of whether or not intravenous&#xD;
      immunoglobulin (IVIG) may impact the hospital length of stay, if started within 48 of&#xD;
      mechanical ventilation in patients infected with SARS-CoV-2 virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated, open label, 1 arm study to observe the impact of length of&#xD;
      hospitalization by starting IVIG administration within 48 hours of mechanical ventilation.&#xD;
      The exploratory objective is to analyze the blood before, during and after IVIG&#xD;
      administration. The blood will be analyzed for the production of inflammatory and&#xD;
      non-inflammatory cytokines, biomarkers for endothelial injury and biomarkers for coagulation&#xD;
      via Mass Spectrometry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single group, pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Assess hospital length of stay after mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human metabolome and proteome</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Analyze the blood to assess the human metabolome and proteome in patients with COVID-19 receiving IVIG including production of inflammatory and anti-inflammatory cytokines, markers of endothelial injury, and coagulation using Mass Spectrometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>IVIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVIG 0.5gram/kg IVPB using actual body weight daily x 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIG</intervention_name>
    <description>Patients will receive IVIG daily for four days.</description>
    <arm_group_label>IVIG</arm_group_label>
    <other_name>Octagam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed COVID-19 positive test result&#xD;
&#xD;
          2. Initiation of the first dose of IVIG within 72 hours of mechanical ventilation.&#xD;
&#xD;
          3. Age &gt;18 years old.&#xD;
&#xD;
          4. Consenting next of kin having access to an electronic device that is able to access&#xD;
             DocuSignÂ® online and email for consenting.&#xD;
&#xD;
          5. Subjects or their proxy must have the ability to understand the requirements of the&#xD;
             study, provide informed consent, and provide authorization of use and disclosure of&#xD;
             personal health information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Superimposed bacterial pneumonia or bacteremia&#xD;
&#xD;
          2. Severe allergy to any IVIG product formulation&#xD;
&#xD;
          3. Hypersensitivity to corn&#xD;
&#xD;
          4. Uncontrolled hypertension (SBP&gt;180 mm Hg or DBP&gt;120mmHg)&#xD;
&#xD;
          5. Active participant in another research treatment study&#xD;
&#xD;
          6. Advanced dementia&#xD;
&#xD;
          7. Severe renal disease (CrCl&lt; 20 mL/min)&#xD;
&#xD;
          8. Active cancer malignancy&#xD;
&#xD;
          9. Active treatment with cancer chemotherapy or immunotherapy&#xD;
&#xD;
         10. Congestive heart failure clinically or by history (EF&lt; 25%)&#xD;
&#xD;
         11. Prior receipt during admission of any other investigational agent (eg. convalescent&#xD;
             plasma, tocilizumab)&#xD;
&#xD;
         12. Venous or arterial thrombosis &lt; 90 days prior&#xD;
&#xD;
         13. Are receiving cytotoxic or biologic treatments such as TNF inhibitors,&#xD;
             anti-interleukin-1 (IL-1), anti-IL-6 (tocilizumab or sarilumab), T-cell or B-cell&#xD;
             targeted therapies (rituximab), interferon, or Janus kinase (JAK) inhibitors for any&#xD;
             indication at study entry. Note: A washout period 4 weeks (or 5 half-lives, whichever&#xD;
             is longer) is required prior to screening, with the following exceptions:&#xD;
&#xD;
               -  B-cell targeted therapies: a washout period of 24 weeks or 5 half-lives&#xD;
                  (whichever is longer)&#xD;
&#xD;
               -  TNF inhibitors: a washout period of 2 weeks or 5 half-lives (whichever is&#xD;
                  longer), and&#xD;
&#xD;
               -  JAK inhibitor: a washout period of 1 week or 5 half-lives (whichever is longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sakoulas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Miller</last_name>
    <phone>858-939-7161</phone>
    <email>kathryn.miller@sharp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Geriak, PharmD</last_name>
    <phone>858-939-3717</phone>
    <email>matthew.geriak@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathryn Miller</last_name>
      <phone>858-939-7161</phone>
      <email>kathryn.miller@sharp.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>George Sakoulas, MD</investigator_full_name>
    <investigator_title>Infectious Disease Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

